Assuntos
Cadáver , Transplante de Rim/patologia , Túbulos Renais/patologia , Doadores Vivos , Complicações Pós-Operatórias/patologia , Acidose/epidemiologia , Criança , Pré-Escolar , Creatinina/sangue , Quimioterapia Combinada , Feminino , Humanos , Hipopotassemia/epidemiologia , Imunossupressores/uso terapêutico , Lactente , Transplante de Rim/efeitos adversos , Transplante de Rim/fisiologia , Deficiência de Magnésio/epidemiologia , Masculino , Fosfatos/metabolismo , Estudos Prospectivos , Micção/fisiologiaRESUMO
The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome.
